Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: nialamide, phenelzine, minaprine +13 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 422 Parkinson's papers of 4,334 | 0.20 |
| pathways Reactome | 8 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 2924
Sealed predictions
- MAOA in dopamine neurons, braak+0.12 (p 0.749) → -0.06 (p 0.874)receipt 2930
Swarm cases
receipt 2930: MAOA in dopamine neurons, braak
- power
- full sample +0.03 (p 0.894, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.983, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.14, sign flips 5; without severely affected donors +0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAOA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts